MedTrace Logo

Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection

NCT02733029 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-03-06

No results posted yet for this study

Summary

The purpose of this study is to determine the feasibility and efficacy of detecting kidney transplant rejection using contrast enhance ultrasonography with the contrast agent Sonazoid.

Conditions

  • Renal Transplant Rejection

Interventions

DRUG

Sonazoid

Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles

DEVICE

contrast enhanced ultrasonography

Injection of intravenous ultrasound contrast

Sponsors & Collaborators

  • GE Healthcare

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Reza Abdi, MD · Brigham and Women's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-30
Primary Completion
2022-05-30
Completion
2023-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02733029 on ClinicalTrials.gov